United Kingdom Neuromyelitis Optica Spectrum Disorder Therapeutics Market Size and Share 2023 | Upcoming Trends, Development Status and in-Depth Analysis Research Report by 2028

Report Overview

The UK Neuromyelitis Optica Spectrum Disorder (NMOSD) Therapeutics market size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Neuromyelitis Optica Spectrum Disorder (NMOSD) is previously known as Devic Syndrome, a rare and devastating, autoimmune, inflammatory disorder of the central nervous system (CNS) characterized by severe axonal damage, primarily to the optic nerve and the spinal cord, sudden and unpredictable relapses, also known as attacks. Each relapse results in stepwise accumulation of disability, including blindness, paralysis, bowel and bladder dysfunction, and sometimes leads to premature death. Uncontrolled complement activation triggered by anti-AQP4 autoantibodies is a major underlying mechanism of the disease.

The New England Journal of Medicine (NEJM) published positive data regarding the approval of Soliris by the European Medicines Agency (EMA), as a treatment for patients with NMOSD who are anti-AQP4 antibody-positive. Around 97.9 percent of patients receiving SOLIRIS were relapse-free at 48 weeks compared with 63.2 percent of patients receiving placebo. It has been estimated that NMOSD cases rise up to 430/100,000 of the hospital population. Population-based studies over the past two decades showed that Blacks also have a higher NMOSD prevalence than Whites. A study conducted in the UK reported a prevalence rate of 1.8/100,000 among Blacks. In populations with a higher prevalence, the incidence is also higher.

Market Growth Drivers

The emerging markets and huge investment in research and development are the factors responsible for the growth of the NMOSD market. The emergence of new therapies for the acute phase or prevention of NMOSD creates lucrative opportunities for the market.

The NMOSD market is majorly driven by the rise in the incidence of neuromyelitis optica spectrum disorder. In addition, the emergence of drugs used in the prevention of NMOSD and improvement in healthcare facilities are some of the impacting factors that drive the market growth.

Market Restraints

Nevertheless, less trained expertise or technically skilled professionals coupled with high treatment cost significantly hinder the growth of this market.

Get PDF Sample Report Now! @ https://www.prudentmarkets.com/sample-request/139904/

Top Major Players

The major key players operating in UK NMOSD treatment markets are Alexion Pharmaceuticals Inc., Medimmune LLC, AstraZeneca, Hoffmann-La Roche Ltd, Veila Bio and, Genentech Inc. prevailing in the UK market during the forecast period. Eculizumab, Inebilizumab, and Satralizumab are most commonly used for neuromyelitis optica spectrum disorder.

The United Kingdom Neuromyelitis Optica Spectrum Disorder Therapeutics Market 2023 Report makes available the current and forthcoming technical and financial details of the industry. It is one of the most comprehensive and important additions to the Prudent Markets archive of market research studies. It offers detailed research and analysis of key aspects of the global United Kingdom Neuromyelitis Optica Spectrum Disorder Therapeutics market. This report explores all the key factors affecting the growth of the global United Kingdom Neuromyelitis Optica Spectrum Disorder Therapeutics market, including demand-supply scenario, pricing structure, profit margins, production, and value chain analysis.

To Know More About COVID-19 Impact On United Kingdom Neuromyelitis Optica Spectrum Disorder Therapeutics Market @ https://www.prudentmarkets.com/sample-request/139904/

Market Segmentation

By Type:

Based on type, the NMOSD market is segregated into neuromyelitis optica spectrum disorder with aquaporin-4 antibodies and neuromyelitis optica spectrum disorder without aquaporin-4 antibodies. Adults and children with NMOSD demonstrate that myelin oligodendrocyte glycoprotein antibody (MOG-Ab)- associated with younger patients (particularly children) are frequently in males (and do not demonstrate the strong female preponderance seen in AQP4-Ab NMOSD). MOG-Abs are common in children with ADS with both monophasic and relapsing disease courses.

By Treatment:

On the basis of treatment, the NMOSD treatment market can be divided into

C5 Protein Inhibitor
Monoclonal antibodies
Corticosteroids
Immunosuppressants
Plasmapheresis
Immunoglobulin therapy

The medication section is further categorized into C5 Protein Inhibitor, monoclonal antibodies, corticosteroids, immunosuppressive agents, and others. In the UK, the European Medicines Agency (EMA) approved Soliris (eculizumab) as the first approved medical treatment for NMOSD.

By Route of Administration:

Based on the route of administration, the NMOSD treatment of the market can be segmented into

Oral
Parenteral
Others

The parenteral witnesses the huge market growth potential during the forecast period.  As Soliris admixture is administered by intravenous infusion over 35 minutes in adults and 1 to 4 hours in pediatric patients.

By Distribution Channels:

In terms of distribution channels, the NMOSD treatment market has been bifurcated into

Hospital pharmacies
Retail pharmacies
Online pharmacies

The hospital pharmacies segment generated the highest revenue in 2020 and is anticipated to witness growth during the forecast period due to most of the major products are prescription products, which are available in hospital pharmacies.

By End Users:

As per the end-user, the NMOSD treatment market has been segmented into

Hospitals
Homecare
Specialty centers
Others

The Walton Centre in Liverpool, and John Radcliffe Hospital at Oxford, currently provide the best NMOSD treatment in the UK. Thus, the hospitals' segment commands the largest market share in terms of value during the forecast period.

Top Major Players

The major key players operating in UK NMOSD treatment markets are Alexion Pharmaceuticals Inc., Medimmune LLC, AstraZeneca, Hoffmann-La Roche Ltd, Veila Bio and, Genentech Inc. prevailing in the UK market during the forecast period. Eculizumab, Inebilizumab, and Satralizumab are most commonly used for neuromyelitis optica spectrum disorder.

Prudent Markets provides attractive discounts that fit your needs. Customization of the reports as per your requirement is also offered. Get in touch with our sales team, who will guarantee you a report that suits your needs.

Speak To Our Analyst For A Discussion On The Above Findings, And Ask For A Discount On The Report @ https://www.prudentmarkets.com/discount-request/139904/

The report covers the competitive analysis of the market. As the demand is driven by a buyer's paying capacity and the rate of item development, the report shows the important regions that will direct growth. This section exclusively shares insight into the budget reports of big-league members of the market helping key players and new entrants understand the potential of investments in the Global United Kingdom Neuromyelitis Optica Spectrum Disorder Therapeutics Market. It can be better employed by both traditional and new players in the industry for complete know-how of the market.

Strategic Points Covered in Table of Content of Global United Kingdom Neuromyelitis Optica Spectrum Disorder Therapeutics Market:

Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the United Kingdom Neuromyelitis Optica Spectrum Disorder Therapeutics market
Chapter 2: Exclusive Summary - the basic information of the United Kingdom Neuromyelitis Optica Spectrum Disorder Therapeutics Market.
Chapter 3: Displaying the Market Dynamics- Drivers, Trends and Challenges & Opportunities of the United Kingdom Neuromyelitis Optica Spectrum Disorder Therapeutics
Chapter 4: Presenting the United Kingdom Neuromyelitis Optica Spectrum Disorder Therapeutics Market Factor Analysis, Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.
Chapter 5: Displaying the by Type, End User and Region/Country
Chapter 6: Evaluating the leading manufacturers of the United Kingdom Neuromyelitis Optica Spectrum Disorder Therapeutics market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile
Chapter 7: To evaluate the market by segments, by countries and by Manufacturers/Company with revenue share and sales by key countries in these various regions
Chapter 8 & 9: Displaying the Appendix, Methodology and Data Source

Any Questions? Feel Free To Enquire Here. We Will put you on the Right Path @ https://www.prudentmarkets.com/enquiry-request/139904/

Free Customization on the basis of client requirements on Immediate purchase:
1- Free country-level breakdown of any 5 countries of your interest.
2- Competitive breakdown of segment revenue by market players.

Customization of the Report:
This report can be customized to meet the client's requirements. Please connect with our sales team (sales@prudentmarkets.com), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +91 83560 50278 || USA/Canada(Toll Free): 1800-601-6071 to share your research requirements.

Get ready to Recognize the pros and cons of the regulatory framework, local reforms, and its effect on the Industry. Understand how the Leaders in Intelligent Network are keeping themselves one stage forward with our most up-to-date survey analysis.

In conclusion, the United Kingdom Neuromyelitis Optica Spectrum Disorder Therapeutics Market report is a genuine source for accessing the research data which is projected to exponentially grow your business. The report provides information such as economic scenarios, benefits, limits, trends, market growth rates, and figures. SWOT analysis and PESTLE analysis is also incorporated in the report.

Contact Us:
Allan Carter
Andheri, Maharashtra, 400102
USA/Canada(Toll Free): 1800-601-6071
Direct Line: +91 83560 50278
Mail: sales@prudentmarkets.com
Web: www.prudentmarkets.com

About Us:
We are leaders in market analytics, business research, and consulting services for Fortune 500 companies, start-ups, financial & government institutions. Since we understand the criticality of data and insights, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available. To be at our client's disposal whenever they need help on market research and consulting services. We also aim to be their business partners when it comes to making critical business decisions around new market entry, M&A, competitive Intelligence and strategy.

This release was published on openPR.